Clinical Trial

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Study acronym: IZAR-1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Protocol Amendment History 1 change
notable Trial sites expanded: 169 -> 182 locations 2026-06-13
Trial Details
NCT Number NCT06641076
Lead Sponsor MoonLake Immunotherapeutics AG
Conditions Arthritis, Psoriatic
Enrollment 960 participants
Start Date 2024-10-15
Primary Completion 2027-02-04 (estimated)
Study Completion 2027-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-12